Skip to content

Influence of Perioperative Fluid Therapy on Hemoglobin and Methemoglobin Levels

Influence of Perioperative Fluid Therapy on Hemoglobin and Methemoglobin Levels in Major Abdominal Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03220620
Enrollment
60
Registered
2017-07-18
Start date
2017-07-14
Completion date
2020-01-01
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative/Postoperative Complications, Fluid Overload, Hemoglobin H

Keywords

fluid therapy, perioperative, hemodilution

Brief summary

The objective of the study is to evaluate influence of perioperative fluid therapy on Methemoglobin levels, and to changes in hemoglobin. Further, changes in Methemoglobin will be related to metabolic signs of oxidative stress (changes in blood lactate). Patients undergoing major abdominal surgery will be included into the study.

Detailed description

Increasing plasma volume by intravenous administration of crystalloid and/or colloid solutions may cause a relative reduction in hemoglobin (Hb) concentration, a situation that is termed 'dilutional anemia'. Such hemodilution may lead to an iatrogenic reduction in oxygen-carrying capacity and the development of organ dysfunction. Paradoxically, large amounts of fluids that are administered with the aim of increasing oxygen delivery (DO2), as is frequently done as part of perioperative goal-directed therapy; this may lead to an actual decrease in the DO2 due to a decrease in Hb concentration. Another potential parameter that may reflect the development of dilutional anemia is methemoglobin (MetHb), a form of Hb with reduced ability for oxygen binding. Experimental studies showed that dilutional anemia may lead to up-regulation of perivascular nitric oxide synthase (NOS) and increase NOS-derived nitric oxide (NO) leading to local vasodilation and oxidization of Hb to MetHb. MetHb may potentially serve as a biomarker of 'anemic stress' associated with reduced tissue perfusion during acute hemodilution.

Interventions

OTHERGDT

individualized fluid therapy

Sponsors

University of Rostock
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* major abdominal surgery * informed consent

Exclusion criteria

* violation of study protocol

Design outcomes

Primary

MeasureTime frameDescription
Influence of perioperative fluid therapy on hemoglobin levelsduring surgeryInfluence of perioperative fluid therapy on hemoglobin levels
Influence of perioperative fluid therapy on Methemoglobin levelsduring surgeryInfluence of perioperative fluid therapy on Methemoglobin levels

Secondary

MeasureTime frameDescription
Influence of perioperative fluid therapy on changes in lactateduring surgeryInfluence of perioperative fluid therapy on changes in lactate
Influence of perioperative fluid therapy on SvO2during surgeryInfluence of perioperative fluid therapy on SvO2

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026